how are glp 1 drugs administered GLP-1 and Anesthesia: Considerations and Cautions for CRNAs GLP−1 receptor agonists for the

Recent studies suggest that glucagon receptor signaling is disrupted in NAFLD, indicating that supra-physiological glucagon receptor agonism might represent a new NAFLD treatment target

40 Preclinical studies have shown that these effects are mainly mediated trough the effects of GLP-1R activation in the central nervous system (CNS) by the modulation of orexigenic and anorexigenic signaling pathways

The pathogenic mechanism involves mutations in the KRAS and p53 genes

Future research directions include direct comparative trials between various GLP-1 RAs and multi-agonists in MASLD populations to identify optimal therapeutic choices for specific patient subgroups

While the mechanisms for GLP-1RAs primary insulinotropic effects are clear, such clarity is not apparent for their other effects